Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Luminex Corporation Receives U.S. FDA Clearance for MAGPIX® Instrument

Published: Monday, April 15, 2013
Last Updated: Monday, April 15, 2013
Bookmark and Share
Innovative multiplexing instrument for clinical laboratories with simultaneous testing for greater than 90% of bacterial, viral, and parasitic causes of infectious gastroenteritis in a single molecular test.

Luminex Corporation announced it has received U.S. FDA clearance of its MAGPIX instrument, with its xTAG Gastrointestinal Pathogen Panel (xTAG GPP). This is the first clinical assay to be cleared on MAGPIX. xTAG GPP is the first U.S. IVD cleared test that can simultaneously detect 11 common viral, bacterial, and parasitic causes of infectious gastroenteritis from a single patient sample.

"Receiving FDA clearance of MAGPIX opens the door for clinical laboratories of all sizes to use xTAG GPP on this innovative instrument," said Patrick J. Balthrop, president and chief executive officer of Luminex. "By bringing a compact, cost-effective, easy-to-deploy multiplexing solution to the clinical market, MAGPIX makes molecular testing more accessible to all laboratories."

Based on Luminex's xMAP® Technology, the easy-to-use MAGPIX instrument is a versatile multiplexing platform capable of performing qualitative and quantitative analysis of proteins and nucleic acids in a variety of sample matrices. MAGPIX is compact making it attractive to laboratories with limited bench space. This affordable system can perform up to 50 different tests in a single reaction volume, greatly reducing sample input, reagents, and labor while improving productivity.

Traditional GI testing technologies and methods can take several days to deliver a single result depending on the pathogen. xTAG GPP is capable of delivering multiple results within five hours. Simultaneous molecular testing on a single sample within a single shift provides significant benefits to laboratories in terms of workflow and resource utilization.

"Tests such as the xTAG GPP that can detect viruses, bacteria, and parasites from one sample at the same time can help clinicians more quickly identify and treat what's causing gastroenteritis," said Alberto Gutierrez, Ph.D., director of the Office of In Vitro Diagnostics and Radiology at the FDA's Center for Devices and Radiological Health in an FDA press release when xTAG GPP was first approved by the Agency. "The test could also allow clinicians and public health professionals to more quickly identify and investigate the source of potential gastroenteritis outbreaks."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Luminex SYNCT Software Receives FDA Clearance, CE Mark
Company has announced that its SYNCT™ Software has received both U.S. FDA clearance and CE Marking for use with its ARIES® System and NxTAG® assays on the MAGPIX® System.
Friday, April 15, 2016
Luminex Receives CE-IVD Mark for ARIES System
The ARIES® System and ARIES®HSV 1&2 Assay previously received FDA clearance in October 2015 and were subsequently launched in the U.S. market.
Tuesday, March 22, 2016
Luminex, University of Sao Paulo Collaborate
Luminex Corporation has announced it is collaborating with the Laboratory of Molecular Evolution & Bioinformatics, Biomedical Sciences Institute, University of São Paulo, Brazil to validate a multi-analyte Zika virus assay developed by Luminex partner,GenArraytion, Inc.
Monday, February 29, 2016
Luminex Corporation Announces Collaboration with University of Sao Paulo
Company has announced collaboration to validate a multi analyte zika virus detection panel for detect multiple disease agent.
Friday, February 26, 2016
Luminex Corporation Receives Medical Device License
Company has announced that it has received medical device licenses from Health Canada's Therapeutic Products Directorate for ARIES System and ARIES HSV 1&2 Assay.
Tuesday, February 23, 2016
Luminex and Bio-Techne Extend and Expand Partnership
Company expands global distribution of award-winning multiplexing instrumentation.
Friday, October 23, 2015
Luminex Receives FDA Clearance
Company has received clearance for ARIES® System and ARIES® HSV 1&2 Assay.
Thursday, October 08, 2015
Luminex Receives FDA and European Clearance for xTAG® CYP2C19 Kit
New cytochrome P450 2C19 assay helps physicians optimize individual patient care.
Tuesday, September 24, 2013
Luminex Corporation Reports Second Quarter 2013 Results
Achieves milestone selling 10,000th multiplexing analyzer.
Tuesday, July 30, 2013
Luminex Receives FDA and European Clearance for New Version of xTAG® CYP2D6 Kit
Luminex submits xTAG® CYP2C19 kit to FDA for review.
Tuesday, July 16, 2013
Merck and Luminex Corporation Enter Agreement
Collaboration to support patient selection for the clinical development of MK-8931, Merck’s lead investigational medicine for Alzheimer’s disease.
Thursday, July 04, 2013
Luminex Corporation Reports First Quarter 2013 Results
Gained FDA clearance for novel Gastrointestinal Pathogen Panel.
Thursday, May 02, 2013
Luminex Receives FDA Clearance for xTAG Gastrointestinal Pathogen Panel
xTAG® GPP simultaneously tests for greater than 90% of bacterial, viral, and parasitic causes of infectious gastroenteritis in a single molecular test.
Tuesday, April 23, 2013
Luminex Corporation Awarded $11 Million Contract by Defense Threat Reduction Agency (DTRA)
Department of Defense award accelerates development of Luminex bio-threat detection technology program.
Thursday, August 16, 2012
Luminex Awarded $11 Million Contract by DTRA
Department of defense award accelerates development of Luminex bio-threat detection technology program.
Tuesday, August 14, 2012
Scientific News
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Magnetic Nanoparticles May Reveal Early Traces Of Cancer
Rice University students’ computer program aids MD Anderson diagnostic initiative .
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
World-First Blood Test For Parkinson's
La Trobe University researchers have developed a world-first diagnostic blood test which could change the lives of people with Parkinson's disease.
Parsortix Demonstrates Benefits Over Marker-Based Systems
Research published online in the International Journal of Cancer, shows the ParsortixTM System efficiently captures and harvests intact, viable circulating tumour cells (CTCs), including EpCAM-negative CTCs, to allow for broader downstream CTC analysis.
Hepatitis C Virus Testing Guidelines Miss Too Many Cases
Urban emergency departments a good place to enact universal screening for adults.
NIH Sequences Genome of a Fungus
Researchers at the Institute have sequenced genome of human, mouse and rat Pneumocystis that cause life-threatening Pneumonia in immunosuppressed hosts.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!